Credit Suisse Ag Cassava Sciences Inc Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Cassava Sciences Inc stock. As of the latest transaction made, Credit Suisse Ag holds 51,154 shares of SAVA stock, worth $141,185. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,154

Previous 49,945 2.42%

Holding current value

$141,185

Previous $1.12 Million 7.74%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$18.44 - $26.41 $22,293 - $31,929	1,209 Added 2.42%	51,154 $1.04 Million
Q4 2023 Feb 08, 2024	BUY	$12.64 - $30.11 $29,350 - $69,915	2,322 Added 4.88%	49,945 $1.12 Million
Q3 2023 Nov 13, 2023	SELL	$16.64 - $25.32 $26,890 - $40,917	-1,616 Reduced 3.28%	47,623 $792,000
Q2 2023 Aug 11, 2023	BUY	$21.59 - $27.88 $97,500 - $125,906	4,516 Added 10.1%	49,239 $1.21 Million
Q1 2023 May 10, 2023	BUY	$23.46 - $36.44 $63,506 - $98,643	2,707 Added 6.44%	44,723 $1.08 Million

Q4 2022 Feb 13, 2023	BUY	$27.82 - $44.16 $230,071 - $365,203	8,270 Added 24.51%	42,016 $1.24 Million
Q3 2022 Nov 10, 2022	SELL	$16.33 - $51.06 $67,116 - $209,856	-4,110 Reduced 10.86%	33,746 $1.41 Million
Q2 2022 Aug 12, 2022	BUY	$17.22 - $38.47 $21,335 - $47,664	1,239 Added 3.38%	37,856 $1.07 Million
Q1 2022 May 16, 2022	BUY	$32.6 - $53.05 $117,001 - $190,396	3,589 Added 10.87%	36,617 $1.36 Million
Q4 2021 Feb 14, 2022	BUY	$36.77 - $90.91 $231,577 - $572,551	6,298 Added 23.56%	33,028 $1.44 Million
Q3 2021 Nov 12, 2021	BUY	$41.79 - $135.3 $216,973 - $702,477	5,192 Added 24.11%	26,730 $1.66 Million
Q2 2021 Aug 16, 2021	BUY	$32.15 - $89.72 $692,446 - $1.93 Million	21,538 New	21,538 $1.84 Million

Others Institutions Holding SAVA

# of Institutions

136

Shares Held

15.9M

Call Options Held

1.26M

Put Options Held

791K

View Full List

About CASSAVA SCIENCES INC

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $111M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

More about SAVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account